|1.||Guo, Chuanlong: 1 article (08/2014)|
|2.||Wu, Xianggen: 1 article (08/2014)|
|3.||Han, Shasha: 1 article (08/2014)|
|4.||Jiang, Haoran: 1 article (08/2014)|
|5.||Liu, Ting: 1 article (08/2014)|
|6.||González-González, Gabriel: 1 article (01/2009)|
|7.||Juárez-Verdayes, Marco A: 1 article (01/2009)|
|8.||Cancino-Díaz, Mario E: 1 article (01/2009)|
|9.||Cancino-Díaz, Juan C: 1 article (01/2009)|
|10.||Betanzos-Cabrera, Gabriel: 1 article (01/2009)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
02/01/2003 - "Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. "
03/01/1995 - "In respiratory tract infections with Streptococcus pneumoniae TMS-3 in mice, Q-35 showed a therapeutic effect similar to sparfloxacin and tosufloxacin. "
09/01/1993 - "On the basis of these results, Q-35 appears to be a promising antimicrobial agent in chemotherapy of mycoplasmal infection."
09/01/1993 - "These results suggest that both Q-35 and ofloxacin are effective in the early phase of infection and, moreover, that Q-35 is also effective in the middle stage of infection, when progressive lung alterations and continuous increases in mycoplasmal growth occur. "
03/01/1995 - "Q-35 showed almost the same activity as that of ofloxacin in mice with pyelonephritic infection due to Escherichia coli TMS-3. "
09/01/1993 - "Q-35 and ofloxacin were efficacious following oral administration of 200 mg/kg/day for 5 days, initiated 24 h after infection, while ciprofloxacin was not active. "
|3.||Urinary Tract Infections (Urinary Tract Infection)
09/01/1995 - "[clinical study of balofloxacin on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with inpatients with infectious enteritis. "
09/01/1995 - "Research group of balofloxacin on infectious enteritis]."
09/01/1995 - "[In vitro antibacterial activity of balofloxacin (BLFX) against isolates from patients with bacterial enteritis]."
09/01/1995 - "The efficacy, safety and usefulness of balofloxacin (BLFX) for patients with acute infectious enteritis and the carriers mainly shigellosis, were investigated. "
|5.||Drug Toxicity (Drug Safety)
01/01/2001 - "The incidence of specific adverse events associated with individual fluoroquinolones was reviewed in a five-year post-marketing surveillance (PMS) study in Japan, in which a total adverse drug reaction (ADR) rate of 1.3% was found for levofloxacin, compared to total ADR rates of 3.3% for pazufloxacin, 3.6% for tosufloxacin, 4.5% for gatifloxacin and 5.4% for balofloxacin. "
|6.||Interferon-alpha (Interferon Alfa)
|7.||Ophthalmic Solutions (Eye Drops)
|1.||Drug Therapy (Chemotherapy)